TNM classification of malignant tumors (Breast Cancer Study Group)

Masataka Sawaki, Tadahiko Shien, Hiroji Iwata

Research output: Contribution to journalReview article

Abstract

The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Minor changes are to add the post-neoadjuvant therapy clinical and pathological classification and to define the size of tumor, lymph node and metastasis components more precisely. Little has changed in the Union for International Cancer Control. We have identified key points of change in both eighth editions of the tumor, lymph node and metastasis classifications and we discuss possible problems which may arise when they are adopted in Japanese practice, as well as future directions.

Original languageEnglish
Pages (from-to)228-231
Number of pages4
JournalJapanese journal of clinical oncology
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Neoplasm Staging
Breast Neoplasms
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Joints
Neoadjuvant Therapy
Biological Factors
Progesterone Receptors
Tumor Biomarkers
Estrogen Receptors
Recurrence

Keywords

  • AJCC
  • Breast cancer
  • Eighth edition
  • TNM classification
  • UICC

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

TNM classification of malignant tumors (Breast Cancer Study Group). / Sawaki, Masataka; Shien, Tadahiko; Iwata, Hiroji.

In: Japanese journal of clinical oncology, Vol. 49, No. 3, 01.03.2019, p. 228-231.

Research output: Contribution to journalReview article

@article{545ca4237b924891aac8ab82c5c378a1,
title = "TNM classification of malignant tumors (Breast Cancer Study Group)",
abstract = "The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Minor changes are to add the post-neoadjuvant therapy clinical and pathological classification and to define the size of tumor, lymph node and metastasis components more precisely. Little has changed in the Union for International Cancer Control. We have identified key points of change in both eighth editions of the tumor, lymph node and metastasis classifications and we discuss possible problems which may arise when they are adopted in Japanese practice, as well as future directions.",
keywords = "AJCC, Breast cancer, Eighth edition, TNM classification, UICC",
author = "Masataka Sawaki and Tadahiko Shien and Hiroji Iwata",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/jjco/hyy182",
language = "English",
volume = "49",
pages = "228--231",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - TNM classification of malignant tumors (Breast Cancer Study Group)

AU - Sawaki, Masataka

AU - Shien, Tadahiko

AU - Iwata, Hiroji

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Minor changes are to add the post-neoadjuvant therapy clinical and pathological classification and to define the size of tumor, lymph node and metastasis components more precisely. Little has changed in the Union for International Cancer Control. We have identified key points of change in both eighth editions of the tumor, lymph node and metastasis classifications and we discuss possible problems which may arise when they are adopted in Japanese practice, as well as future directions.

AB - The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging. Minor changes are to add the post-neoadjuvant therapy clinical and pathological classification and to define the size of tumor, lymph node and metastasis components more precisely. Little has changed in the Union for International Cancer Control. We have identified key points of change in both eighth editions of the tumor, lymph node and metastasis classifications and we discuss possible problems which may arise when they are adopted in Japanese practice, as well as future directions.

KW - AJCC

KW - Breast cancer

KW - Eighth edition

KW - TNM classification

KW - UICC

UR - http://www.scopus.com/inward/record.url?scp=85063969907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063969907&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy182

DO - 10.1093/jjco/hyy182

M3 - Review article

VL - 49

SP - 228

EP - 231

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -